NeoGenomics Revenue Up, But Losses Widen Amid Impairment Charges

Ticker: NEO · Form: 10-Q · Filed: Oct 28, 2025 · CIK: 1077183

Sentiment: bearish

Topics: Oncology Diagnostics, Net Loss, Revenue Growth, Cash Burn, Convertible Debt, Impairment Charges, Biotech

Related Tickers: NEO

TL;DR

**NEO is burning cash and widening losses despite revenue growth, signaling potential financial strain ahead.**

AI Summary

NEOGENOMICS INC reported a significant increase in net revenue for the three months ended September 30, 2025, reaching $187.8 million, up from $167.8 million in the prior year, representing an 11.9% increase. However, the company experienced a substantial rise in net loss, widening to $27.1 million for the quarter, compared to a net loss of $17.7 million in the same period of 2024. For the nine months ended September 30, 2025, net revenue grew to $537.2 million from $488.6 million, an increase of 9.9%, but the net loss deepened to $98.1 million from $63.4 million. Key business changes include the company becoming self-insured for employee health care benefits starting January 2025, recording a self-insurance liability of $2.8 million as of September 30, 2025. The company also recognized significant impairment charges of $7.1 million for the quarter and $27.1 million for the nine months ended September 30, 2025. Cash and cash equivalents decreased sharply from $367.0 million at December 31, 2024, to $164.1 million at September 30, 2025, primarily due to the repayment of $201.3 million in convertible debt. The strategic outlook is challenged by increasing operating expenses, including a rise in general and administrative expenses to $69.9 million for the quarter and research and development expenses to $8.7 million.

Why It Matters

This filing reveals a mixed picture for investors: while NEOGENOMICS INC is growing its top-line revenue, its profitability is deteriorating, with net losses significantly widening. The substantial cash burn, driven by convertible debt repayment and ongoing operational losses, could raise concerns about future liquidity and financing needs, especially for a company in the capital-intensive oncology diagnostic sector. Competitively, increasing R&D and sales & marketing expenses suggest continued investment in market share, but the impairment charges indicate potential struggles with asset utilization or strategic investments. Employees might face pressure if losses continue, while customers could benefit from continued investment in diagnostic services, assuming the company can sustain its operations effectively in a competitive landscape.

Risk Assessment

Risk Level: high — The company's net loss significantly widened to $98.1 million for the nine months ended September 30, 2025, from $63.4 million in the prior year, indicating deteriorating profitability. Cash and cash equivalents plummeted from $367.0 million to $164.1 million, a 55.3% decrease, largely due to a $201.3 million repayment of convertible debt, which could impact future liquidity. Additionally, impairment charges of $27.1 million for the nine-month period suggest potential issues with asset values or business segments.

Analyst Insight

Investors should exercise caution and thoroughly evaluate NEOGENOMICS INC's cash flow projections and future financing plans. Consider reducing exposure or holding off on new investments until there's clear evidence of improved profitability and a stabilized cash position, as the current trend of widening losses and significant cash burn is unsustainable.

Financial Highlights

debt To Equity
0.64
revenue
$537.2M
operating Margin
-19.1%
total Assets
$1,374.8M
total Debt
$879.1M
net Income
-$98.1M
eps
-$0.77
gross Margin
42.9%
cash Position
$164.1M
revenue Growth
+9.9%

Revenue Breakdown

SegmentRevenueGrowth
Net Revenue$187.8M+11.9%
Net Revenue (YTD)$537.2M+9.9%

Key Numbers

Key Players & Entities

FAQ

What were NEOGENOMICS INC's net revenues for the third quarter of 2025?

NEOGENOMICS INC reported net revenues of $187,797 thousand for the three months ended September 30, 2025, an increase from $167,824 thousand in the same period of 2024.

How much was NEOGENOMICS INC's net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, NEOGENOMICS INC's net loss was $98,144 thousand, significantly higher than the $63,402 thousand net loss reported for the same period in 2024.

What was the change in NEOGENOMICS INC's cash and cash equivalents?

NEOGENOMICS INC's cash and cash equivalents decreased by $202,895 thousand, from $367,012 thousand at the beginning of the period to $164,117 thousand as of September 30, 2025.

Did NEOGENOMICS INC incur any impairment charges in 2025?

Yes, NEOGENOMICS INC recognized impairment charges of $7,086 thousand for the three months ended September 30, 2025, and $27,127 thousand for the nine months ended September 30, 2025.

What was the impact of convertible debt on NEOGENOMICS INC's cash flow?

NEOGENOMICS INC repaid $201,250 thousand of convertible debt during the nine months ended September 30, 2025, which was a major factor in the net cash used in financing activities.

What is NEOGENOMICS INC's self-insurance liability as of September 30, 2025?

As of September 30, 2025, NEOGENOMICS INC has recorded a self-insurance liability of $2.8 million, following its transition to self-insured employee health care benefits in January 2025.

How did NEOGENOMICS INC's operating expenses change in Q3 2025?

Total operating expenses for NEOGENOMICS INC increased to $107,460 thousand for the three months ended September 30, 2025, from $96,077 thousand in the prior year, driven by higher general and administrative, R&D, and sales and marketing costs, plus impairment charges.

What is NEOGENOMICS INC's strategy regarding goodwill impairment?

NEOGENOMICS INC performs a qualitative assessment annually in the fourth quarter, or more frequently if impairment indicators exist. For Q3 2025, a quantitative analysis was performed after a qualitative assessment, determining no goodwill impairment as the reporting units' fair values exceeded their carrying values.

What are the primary services offered by NEOGENOMICS INC?

NEOGENOMICS INC and its subsidiaries provide a wide range of oncology diagnostic testing and consultative services, including technical laboratory services and professional interpretation of laboratory test results by licensed physicians specializing in pathology and oncology.

What are the key risks highlighted in NEOGENOMICS INC's 10-Q filing?

The filing references risks from its Annual Report on Form 10-K filed on February 18, 2025, and previous 10-Q filings, including those related to strategy, future operations, changing reimbursement levels, and the timing and benefits of collaborations, indicating ongoing operational and financial uncertainties.

Risk Factors

Industry Context

NeoGenomics operates in the oncology diagnostics sector, providing specialized testing and interpretation services. The industry is characterized by rapid technological advancements, increasing demand for personalized medicine, and a competitive landscape with both large players and niche providers. Regulatory scrutiny and reimbursement policies are also key factors influencing market dynamics.

Regulatory Implications

The company must adhere to various healthcare regulations, including those related to laboratory practices (CLIA) and data privacy (HIPAA). Changes in reimbursement rates from government and private payers can significantly impact revenue. Compliance with evolving diagnostic testing standards and potential new regulations for genetic testing are ongoing considerations.

What Investors Should Do

  1. Monitor expense control measures
  2. Assess cash burn rate and liquidity
  3. Evaluate the impact of impairment charges
  4. Analyze revenue growth drivers

Key Dates

Glossary

Impairment charges
A reduction in the carrying value of an asset when its fair value is less than its book value, indicating a loss in value. (Significant charges of $27.1M for the nine months ended Sept 30, 2025, negatively impacted the company's net income.)
Self-insurance liability
An amount set aside to cover potential claims for benefits (like health care) when a company chooses to self-insure rather than purchase insurance. (A new liability of $2.8M was recorded as of Sept 30, 2025, due to the company becoming self-insured for employee health care.)
Convertible senior notes
Debt securities that can be converted into a predetermined amount of the issuer's equity at certain times. (The company repaid $201.3M of these notes, significantly reducing its cash position.)
Goodwill
An intangible asset that arises when one company acquires another for a price greater than the fair value of its net identifiable assets. (The company has significant goodwill ($524.3M as of Sept 30, 2025), with $5.1M added from the Pathline acquisition.)
Operating lease right-of-use assets
Assets recognized under accounting standards for leases, representing the right to use an asset for the lease term. (These assets, along with related liabilities, are a significant component of the company's balance sheet.)

Year-Over-Year Comparison

Compared to the prior year, NeoGenomics has demonstrated revenue growth, with net revenue increasing by 11.9% in Q3 2025 and 9.9% year-to-date. However, this top-line growth has been overshadowed by a significant deterioration in profitability, with net losses widening considerably. Key balance sheet changes include a substantial reduction in cash and cash equivalents due to debt repayment and an increase in liabilities, including a new self-insurance liability. New risks related to impairment charges and the integration of acquisitions have also emerged.

Filing Stats: 4,627 words · 19 min read · ~15 pages · Grade level 18 · Accepted 2025-10-28 16:05:09

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 27

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 38

Controls and Procedures

Item 4. Controls and Procedures 38

OTHER INFORMATION

PART II OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 39

Risk Factors

Item 1A. Risk Factors 39

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 39

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 39

Other Information

Item 5. Other Information 39

Exhibits

Item 6. Exhibits 40

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intends," "may," "plan," "potential," "project," "will," "would," and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements address various matters, including the Company's strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, expected synergies of the Pathline Acquisition, the timing, performance and anticipated benefits of collaboration, partnership and licensing activities, projected costs and capital expenditures, prospects and plans, and objectives of Management. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the "SEC") on February 18, 2025, in Part II, Item 1A, "Risk Factors" in our Quarterly Report on Form 10-Q as filed with the SEC on April 29, 2025, and in Part II, Item 1A, "Risk Factors" in this Quarterly Report on Form 10-Q. The forward-looking statements included in this Quarterly Report on Form 10-Q speak only as of the date of this report, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS NEOGENOMICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) (unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets Cash and cash equivalents $ 164,117 $ 367,012 Marketable securities, at fair value — 19,832 Accounts receivable, net 155,296 150,540 Inventories 28,460 26,748 Prepaid assets 21,986 20,165 Other current assets 10,528 11,722 Assets held for sale (Note 3) 2,078 — Total current assets 382,465 596,019 Property and equipment (net of accumulated depreciation of $ 208,977 and $ 189,990 , respectively) 85,470 94,103 Operating lease right-of-use assets 80,150 79,583 Intangible assets, net 294,162 339,681 Goodwill 524,344 522,766 Other assets 8,189 5,886 Total non-current assets 992,315 1,042,019 Total assets $ 1,374,780 $ 1,638,038 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 22,611 $ 21,607 Accrued compensation 51,301 62,443 Accrued expenses and other liabilities 17,393 12,624 Current portion of operating lease liabilities 4,507 3,381 Current portion of convertible senior notes, net — 200,777 Contract liabilities 1,576 409 Liabilities held for sale (Note 3) 478 — Total current liabilities 97,866 301,241 Long-term liabilities Operating lease liabilities 64,325 60,841 Convertible senior notes, net 341,476 340,335 Deferred income tax liabilities, net 20,846 21,510 Other long-term liabilities 11,977 11,772 Total long-term liabilities 438,624 434,458 Total liabilities $ 536,490 $ 735,699 Commitments and contingencies (Note 12) Stockholders' equity Common stock, $ 0.001 par value, ( 250,000,000 shares authorized; 128,885,101 and 128,145,333 shares issued and outstanding, respectively) $ 128 $ 128 Additional paid-in capital 1,262,016 1,228,198 Accumulated other comprehensive income (loss) 71 ( 206 ) Accumulated deficit ( 423,925 ) ( 325,781 ) Total stockholders' equity $ 838,290 $ 902,339 Total liabilities a

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 1. Nature of the Business NeoGenomics, Inc., a Nevada corporation (the "Company" or "NeoGenomics"), and its subsidiaries provide a wide range of oncology diagnostic testing and consultative services which includes technical laboratory services and professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. The Company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying interim Condensed Consolidated Financial Statements ("Consolidated Financial Statements") are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements. The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, except for new accounting standards discussed under Recent Accounting Pronouncements. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in the Company's annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in the accompanying interim Consolidated Financial Statements and footnotes. Accordingly, the accompanying interim unaudited Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. The results of operations presented in

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) performed by comparing the fair value of the reporting unit to its carrying value. If the carrying value is greater than the estimate of fair value, an impairment loss will be recognized for the amount in which the carrying amount exceeds the reporting unit's fair value. The Company estimates the fair values of its reporting units using a combination of the income, or discounted cash flows approach and the market approach, which utilizes comparable companies' data. During the third quarter of 2025, the Company performed a qualitative assessment to determine whether it was more likely than not that the fair values of its reporting units were less than their carrying values. Such qualitative factors included macroeconomic conditions, industry and market considerations, and other relevant events. As a result of the qualitative assessment, the Company determined that there were indicators that it was more likely than not that the fair values of its reporting units were less than their carrying values. Accordingly, the Company performed a quantitative analysis and determined the reporting units' fair values exceeded the reporting units' carrying values and there was no impairment of the recorded goodwill as of September 30, 2025. Self-Insurance Beginning in January 2025, the Company became self-insured for its employee health care benefits. Liabilities for self-insured exposures are accrued for the amounts expected to be paid based on historical claims experience and actuarial data for forecasted settlements of claims filed and for incurred but not yet reported claims. As of September 30, 2025, the Company has recorded self-insurance liability of $ 2.8 million. The Company's estimate is subject to inherent variability which may lead to ultimate payments being either greater or less than the amounts presented above. Self-insurance liabilities have been classified as a current liability in accrued compensation on

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) The acquisition of Pathline was determined to be a business combination and has been accounted for using the acquisition method. The purchase price and purchase price allocation were based upon Management's best estimates and assumptions and were considered preliminary as of September 30, 2025, and are subject to future revision. The following table summarizes the estimated purchase consideration recorded for the acquisition of Pathline, the estimated fair value of the net assets acquired and liabilities assumed, and the preliminary calculation of goodwill based on the excess of the consideration transferred over the fair value of the net assets acquired and liabilities assumed at the Pathline Acquisition Date (in thousands, except per share data): April 4, 2025 (as initially reported) Measurement Period Adjustments April 4, 2025 (as adjusted) Purchase consideration: Initial cash consideration, net (1) $ 7,275 $ 220 $ 7,495 Contingent consideration 1,000 — 1,000 Total purchase consideration $ 8,275 $ 220 $ 8,495 Allocation of the purchase consideration: Cash and cash equivalents $ 317 $ — $ 317 Accounts receivable, net 3,324 — 3,324 Inventories 657 — 657 Prepaid and other current assets 443 — 443 Intangible assets 1,200 — 1,200 Property and equipment 1,264 — 1,264 Operating lease right-of-use assets 6,632 ( 235 ) 6,397 Other non-current assets 200 — 200 Total identifiable assets acquired 14,037 ( 235 ) 13,802 Total identifiable liabilities assumed 10,602 ( 217 ) 10,385 Net identifiable assets acquired 3,435 ( 18 ) 3,417 Goodwill 4,840 238 5,078 Total purchase consideration $ 8,275 $ 220 $ 8,495 (1) Includes net adjustments of $ 0.7 million reflective of cash and other ad

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing